Fremont, California – Further evidence on the low bleeding profile of Verseon’s novel family of anti-coagulants was presented at the BioEurope conference in Stockholm, Sweden last week. The new data reinforces the promise of Verseon’s novel, highly selective direct thrombin inhibitors (DTIs) as a potential treatment for venous thrombotic disorders while maintaining a lower bleeding risk than current drugs.

The latest preclinical trial results, based on a stasis-induced venous thrombosis model, adds to the list of successful studies performed by the company and broadens the therapeutic potential of Verseon’s DTIs to a wide range of thrombotic disorders, including stroke prevention for atrial fibrillation patients, deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.

About Verseon’s Anticoagulant Program

Verseon’s new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of the company’s proprietary, computational drug discovery platform. The novel small-molecule DTIs act through reversible covalent inhibition, a unique mode of action that leads to novel pharmacology, including lower bleeding liability as seen in multiple laboratory tests. In addition to efficacy and lower bleeding risk, Verseon’s new class of anticoagulants also has pharmacokinetic properties suitable for oral dosing.

About Verseon

Verseon is a technology-based pharmaceutical company that employs its proprietary computational drug discovery platform to develop novel therapeutics for today’s challenging diseases. Verseon’s platform can consistently design novel drugs that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and solid tumor cancers.